Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies

Bone Marrow Transplantation

Volumn 31, Issue 1, 2003, Pages 45-50

  Kyriacou, C ^a   Kottaridis, P D ^a   Eliahoo, J ^a   McKeag, N ^a   Bomford, J ^a   McGarrigle, H H ^a   Linch, D C ^a   Mackinnon, S ^a   Chatterjee, R ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Germ cell; Leydig cell insufficiency; Non myeloablative transplants

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; FOLLITROPIN; LUTEINIZING HORMONE; MELPHALAN; TESTOSTERONE;

ADULT; ARTICLE; AUTOGRAFT; BONE MARROW TRANSPLANTATION; CELL DAMAGE; CELL FUNCTION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; GERM CELL; GONAD DYSFUNCTION; HEMATOLOGIC MALIGNANCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LEYDIG CELL; LONGITUDINAL STUDY; MALE; MALE INFERTILITY; PATIENT COUNSELING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; REPRODUCTIVE TOXICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TESTIS DISEASE; TESTIS FUNCTION; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; DRUG THERAPY, COMBINATION; FOLLICLE STIMULATING HORMONE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LEYDIG CELLS; LONGITUDINAL STUDIES; LUTEINIZING HORMONE; LYMPHOMA; MALE; MIDDLE AGED; TESTOSTERONE; TIME FACTORS;

EID: 0037259636     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703777     Document Type: Article

References (14)

1. Chatterjee R, Goldstone AH. Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Bone Marrow Transplant 1996; 17: 5-11.
2. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update 2001; 7: 363-369.
3. Chatterjee R, Mills W, Katz M et al. Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma. Bone Marrow Transplant 1994; 13: 519-522.
4. Salooja N, Szydlo RM, Socie G et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001; 358: 271-276.
5. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
6. Russell LB, Hunsicker PR, Shelby MD. Melphalan, a second chemical for which specific-locus mutation induction in the mouse is maximum in early spermatids. Mutat Res 1992; 282: 151-158.
7. Witt KL, Bishop JB. Mutagenicity of anticancer drugs in mammalian germ cells. Mutat Res 1996; 355: 209-234.
8. Generoso WM, Witt KL, Cain KT et al. Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice. Mutat Res 1995; 345: 167-180.
9. Chatterjee R, Haines GA, Perera DM et al. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000; 15: 762-766.
10. Chatterjee R, Kottaridis PD, McGarrigle HH et al. Patterns of Leydig cell insufficiency in adult males following bone marrow transplantation for haematological malignancies. Bone Marrow Transplant 2001; 28: 497-502.
11. Grigg AP, McLachlan R, Zaja J, Szer J. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120mg/kg). Bone Marrow Transplant 2000; 26: 1089-1095.
12. Singhal S, Powles R, Treleaven J et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996; 18: 1049-1055.
13. Kirchhoff C. CD52 is the 'major maturation-associated' sperm membrane antigen. Mol Hum Reprod 1996; 2: 9-17.
14. Sanders JE, Hawley J, Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-3052.